Dr Katherine Bowen, PhD, is Vice President of Regulatory Affairs at Boyds. She leads the award-winning regulatory team, supporting clients across the globe.
With over 16 years’ experience in regulatory affairs spanning both mid-sized to large pharma and consultancies, Katherine has worked across a broad range of therapeutic areas from early phase to regulatory approval with a focus on the US and EU.
Before joining Boyds, Katherine served as Head of Regulatory Teams and Principal Consultant at DLRC, where she led a team of regulatory consultants and provided both strategic and operational regulatory advice to a diverse range of clients. Prior to that, she held various global, international, and EU regulatory roles at companies such as Eli Lilly and Amgen.
Katherine joined Boyds in 2022 as Senior Director of Regulatory Affairs. Since then, she has led client projects, providing strategic and operational regulatory advice to facilitate regulatory input, incentives, and early market access. She became Vice President of Regulatory Affairs in December 2024.
Katherine’s specialist areas of expertise include oncology, clinical development, and marketing authorisation applications (MAAs).
She holds a PhD in Neuroscience from the University of Cambridge and graduated with first class honours in Neuroscience from the University of Nottingham. In 2023, Katherine won The Organisation for Professionals in Regulatory Affairs (TOPRA) Inspiration Award recognising her achievements as a mentor and leader.
Dr Katherine Bowen PhD, BSc (Hons)
Vice President, Regulatory Affairs
T +44 (0)1270 270010
E katherine.bowen@boydconsultants.com
